Most researchers looking for CJC-1295 in Parla quickly find that local retail options are all but absent from local stores. This global online supply model is ultimately a quality advantage — top vendors distinguish themselves through rigorous testing in ways no local retailer can match. Separating properly characterised CJC-1295 from the rest of the market comes down to three things: an HPLC chromatogram documenting ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Parla researchers need to know about sourcing, verifying, and handling CJC-1295 for legitimate research applications.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Parla researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade CJC-1295
Quality CJC-1295 sourcing begins with a simple filter: does this vendor make batch-matched COAs available before purchase? Those who make this data freely available are operating transparently. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are below the threshold for research use. Negative indicators in CJC-1295 vendor evaluation: prices significantly below market average, vague sourcing information, no community presence, and COAs that lack endotoxin data. Bacteriostatic water is the standard reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that suppresses bacterial proliferation and extends reconstituted shelf life to 4 weeks when kept refrigerated.
Order CJC-1295 — ships to Parla
COA-verified · International tracking · Research grade
All use of CJC-1295 in Parla or anywhere must be research use only — this compound is not approved for clinical human use, and all handling should follow research laboratory protocols. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; repeated freeze-thaw cycles of reconstituted material should be avoided by preparing small aliquots before storage. The primary quality-related safety risk in CJC-1295 research is bacterial endotoxin from low-quality material — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. The research literature on CJC-1295 should be read critically before planning any study — study methodologies, dosing, and endpoints vary significantly and results do not always generalise across models.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
